Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction

• US 20070049565A1
• Filed: 08/11/2006
• Published: 03/01/2007
• Est. Priority Date: 08/24/2005
• Status: Abandoned Application

• Current Assignee: Neurotec Pharma SL
• Original Assignee: Neurotec Pharma SL
• Inventors: Cho, Sung, Lee, Jae, Shin, Jin, Lee, Young, Cho, Jae, Gwag, Byoung, Byun, Han, Noh, Jae, Lim, Hyang, Kim, Ki
• Application Number:
  US11/503,379
• Publication Number:
  US 20070049565A1
• Time in Patent Office: Days
• US Class Current: 514/159
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/24 having an amino or nitro group
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to a combination of cell necrosis inhibitor and lithium, process for the preparation of the combination, pharmaceutical formulation containing the combination and use of the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The combination of the present invention shows a synergic effect and thus is useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig'"'"'s disease), Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.

Claims

1. A method for treating neuronal death in neurological disease or ocular disease in a human or animal, which comprises administering to the human or animal in need thereof a therapeutically effective amount of a cell necrosis inhibitor and concomitantly or sequentially administering a therapeutically effective amount of lithium or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the neurological disease is selected from amyotrophic lateral sclerosis (ALS, Lou Gehrig'"'"'s disease), Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, stroke, traumatic brain injury, and spinal cord injury.

3. The method of claim 1, wherein the ocular disease is selected from glaucoma, diabetic retinopathy and macular degeneration.

4. The method of claim 1, wherein the cell necrosis inhibitor is at least one selected from:

(i) benzylaminosalicylic acid derivatives of the following formula (I) or pharmaceutically acceptable salts thereof and

(ii) tetrafluorobenzyl derivatives of the following formula (II) or pharmaceutically acceptable salts thereof;

wherein,

X is CO, SO₂ or (CH₂)_n, wherein n is an integer from 1 to 5;

R₁ is hydrogen, alkyl or alkanoyl;

R₂ is hydrogen or alkyl;

R₃ is hydrogen or an acetoxy group; and

R₄ is a phenyl group which is unsubstituted or substituted with one or more of nitro, halogen, haloalkyl, and C₁-C₅ alkoxy;

wherein,

R₁, R₂ and R₃ are independently hydrogen or halogen;

R₄ is hydroxy, alkyl, alkoxy, halogen, alkoxy substituted with halogen, alkanoyloxy or nitro; and

R₅ is carboxyl acid, ester having C₁-C₄ alkyl, carboxyamide, sulfonic acid, halogen or nitro.

5. The method of claim 4, wherein the benzylaminosalicylic acid derivative is at least one selected from:

5-benzylaminosalicylic acid,

5-(4-nitrobenzyl)aminosalicylic acid,

5-(4-chlorobenzyl)aminosalicylic acid,

5-(4-trifluoromethylbenzyl)aminosalicylic acid,

5-(4-fluorobenzyl)aminosalicylic acid,

5-(4-methoxybenzyl)aminosalicylic acid,

5-(4-pentafluorobenzyl)aminosalicylic acid,

5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate,

5-(4-nitrobenzyl)-N-acetylamino-2-hydroxy ethylbenzoate,

5-(4-nitrobenzyl)-N-acetylamino-2-acetoxy ethylbenzoate,

5-(4-nitrobenzoyl)aminosalicylic acid,

5-(4-nitrobenzenesulfonyl)aminosalicylic acid,

5-[2-(4-nitrophenyl)ethyl]aminosalicylic acid,

5-[3-(4-nitrophenyl)-n-propyl]aminosalicylic acid, and

2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid.

6. The method of claim 5, wherein the benzylaminosalicylic acid derivative is 2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid.

7. The method of claim 4, wherein the tetrafluorobenzyl derivative is at least one selected from:

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-nitro-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-chloro-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-bromo-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-methyl-benzylamino)-benzoic acid,

2-methyl-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-methoxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-2-trifluoromethoxy benzoic acid,

2-nitro-4-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)phenol,

2-chloro-4-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-phenol,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzamide,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzenesulfonic acid,

methyl 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoate,

2-ethanoyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-propanoyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, and

2-cyclohexan carbonyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid.

8. The method of claim 7, wherein the tetrafluorobenzyl derivative is 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid.

9. A pharmaceutical formulation for treating neuronal death in neurological disease or ocular disease in a human or animal, which comprises a therapeutically effective amount of a cell necrosis inhibitor and a therapeutically effective amount of lithium or a pharmaceutical acceptable salt thereof.

10. The pharmaceutical formulation of claim 9, wherein the neurological disease is selected from amyotrophic lateral sclerosis (ALS, Lou Gehrig'"'"'s disease), Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, stroke, traumatic brain injury, and spinal cord injury.

11. The pharmaceutical formulation of claim 9, wherein the ocular disease is selected from glaucoma, diabetic retinopathy and macular degeneration.

12. The pharmaceutical formulation of claim 9, wherein the cell necrosis inhibitor is at least one selected from:

(i) benzylaminosalicylic acid derivatives of the following formula (I) or pharmaceutically acceptable salts thereof and

(ii) tetrafluorobenzyl derivatives of the following formula (II) or pharmaceutically acceptable salts thereof;

wherein,

X is CO, SO₂ or (CH₂)_n, wherein n is an integer from 1 to 5;

R₁ is hydrogen, alkyl or alkanoyl;

R₂ is hydrogen or alkyl;

R₃ is hydrogen or an acetoxy group; and

R₄ is a phenyl group which is unsubstituted or substituted with one or more of nitro, halogen, haloalkyl, and C₁-C₅ alkoxy;

wherein,

R₁, R₂ and R₃ are independently hydrogen or halogen;

R₄ is hydroxy, alkyl, alkoxy, halogen, alkoxy substituted with halogen, alkanoyloxy or nitro; and

R₅ is carboxyl acid, ester having C₁-C₄ alkyl, carboxyamide, sulfonic acid, halogen or nitro.

13. The pharmaceutical formulation of claim 12, wherein the benzylaminosalicylic acid derivative is at least one selected from:

5-benzylaminosalicylic acid,

5-(4-nitrobenzyl)aminosalicylic acid,

5-(4-chlorobenzyl)aminosalicylic acid,

5-(4-trifluoromethylbenzyl)aminosalicylic acid,

5-(4-fluorobenzyl)aminosalicylic acid,

5-(4-methoxybenzyl)aminosalicylic acid,

5-(4-pentafluorobenzyl)aminosalicylic acid,

5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate,

5-(4-nitrobenzyl)-N-acetylamino-2-hydroxy ethylbenzoate,

5-(4-nitrobenzyl)-N-acetylamino-2-acetoxy ethylbenzoate,

5-(4-nitrobenzoyl)aminosalicylic acid,

5-(4-nitrobenzenesulfonyl)aminosalicylic acid,

5-[2-(4-nitrophenyl)ethyl]aminosalicylic acid,

5-[3-(4-nitrophenyl)-n-propyl]aminosalicylic acid, and

2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid.

14. The pharmaceutical formulation of claim 13, wherein the benzylaminosalicylic acid derivative is 2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid.

15. The pharmaceutical formulation of claim 12, wherein the tetrafluorobenzyl derivatives is at least one selected from:

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-nitro-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-chloro-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-bromo-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-methyl-benzylamino)-benzoic acid,

2-methyl-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-methoxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-2-trifluoromethoxy benzoic acid,

2-nitro-4-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)phenol,

2-chloro-4-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-phenol,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzamide,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzenesulfonic acid,

methyl 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoate,

2-ethanoyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-propanoyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, and

2-cyclohexan carbonyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid.

16. The pharmaceutical formulation of claim 15, wherein the tetrafluorobenzyl derivatives is 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid.

17. The compound 2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17 and a pharmaceutically acceptable carrier or diluent.

19. A kit for treating neuronal death in neurological disease or ocular disease in a human or animal, which comprises a therapeutically effective amount of a cell necrosis inhibitor and a therapeutically effective amount of lithium or a pharmaceutical acceptable salt thereof.

20. The kit of claim 19, wherein the neurological disease is selected from amyotrophic lateral sclerosis (ALS, Lou Gehrig'"'"'s disease), Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, stroke, traumatic brain injury, and spinal cord injury.

21. The kit of claim 19, wherein the ocular disease is selected from glaucoma, diabetic retinopathy and macular degeneration.

22. The kit of claim 19, wherein the cell necrosis inhibitor is at least one selected from:

(i) benzylaminosalicylic acid derivatives of the following formula (I) or pharmaceutically acceptable salts thereof and

(ii) tetrafluorobenzyl derivatives of the following formula (II) or pharmaceutically acceptable salts thereof;

wherein,

X is CO, SO₂ or (CH₂)_n, wherein n is an integer from 1 to 5;

R₁ is hydrogen, alkyl or alkanoyl;

R₂ is hydrogen or alkyl;

R₃ is hydrogen or an acetoxy group; and

R₄ is a phenyl group which is unsubstituted or substituted with one or more of nitro, halogen, haloalkyl, and C₁-C₅ alkoxy;

wherein,

R₁, R₂ and R₃ are independently hydrogen or halogen;

R₄ is hydroxy, alkyl, alkoxy, halogen, alkoxy substituted with halogen, alkanoyloxy or nitro; and

R₅ is carboxyl acid, ester having C₁-C₄ alkyl, carboxyamide, sulfonic acid, halogen or nitro.

23. The kit of claim 22, wherein the benzylaminosalicylic acid derivative is at least one selected from:

5-benzylaminosalicylic acid,

5-(4-nitrobenzyl)aminosalicylic acid,

5-(4-chlorobenzyl)aminosalicylic acid,

5-(4-trifluoromethylbenzyl)aminosalicylic acid,

5-(4-fluorobenzyl)aminosalicylic acid,

5-(4-methoxybenzyl)aminosalicylic acid,

5-(4-pentafluorobenzyl)aminosalicylic acid,

5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate,

5-(4-nitrobenzyl)-N-acetylamino-2-hydroxy ethylbenzoate,

5-(4-nitrobenzyl)-N-acetylamino-2-acetoxy ethylbenzoate,

5-(4-nitrobenzoyl)aminosalicylic acid,

5-(4-nitrobenzenesulfonyl)aminosalicylic acid,

5-[2-(4-nitrophenyl)ethyl]aminosalicylic acid,

5-[3-(4-nitrophenyl)-n-propyl]aminosalicylic acid, and

2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid.

24. The kit of claim 23, wherein the benzylaminosalicylic acid derivative is 2-hydroxy-5-(2-(4-trifluoromethyl-phenyl)ethylamino)-benzoic acid.

25. The kit of claim 22, wherein the tetrafluorobenzyl derivatives is at least one selected from:

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-nitro-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-chloro-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-bromo-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-methyl-benzylamino)-benzoic acid,

2-methyl-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-methoxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-2-trifluoromethoxy benzoic acid,

2-nitro-4-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)phenol,

2-chloro-4-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-phenol,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzamide,

2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzenesulfonic acid,

methyl 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoate,

2-ethanoyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid,

2-propanoyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, and

2-cyclohexan carbonyloxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid.

26. The kit of claim 25, wherein the tetrafluorobenzyl derivatives is 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid.